1. Home
  2. LGVN vs MDCX Comparison

LGVN vs MDCX Comparison

Compare LGVN & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.94

Market Cap

11.9M

Sector

Health Care

ML Signal

HOLD

Logo Medicus Pharma Ltd.

MDCX

Medicus Pharma Ltd.

HOLD

Current Price

$0.40

Market Cap

13.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGVN
MDCX
Founded
2014
2008
Country
United States
United States
Employees
N/A
12
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.9M
13.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LGVN
MDCX
Price
$0.94
$0.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.00
$23.50
AVG Volume (30 Days)
8.9M
8.8M
Earning Date
03-17-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
50.76
N/A
EPS
N/A
N/A
Revenue
$709,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,183.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.37
52 Week High
$1.83
$8.90

Technical Indicators

Market Signals
Indicator
LGVN
MDCX
Relative Strength Index (RSI) 58.29 28.10
Support Level $0.55 $0.37
Resistance Level $1.44 $1.70
Average True Range (ATR) 0.14 0.05
MACD -0.00 0.01
Stochastic Oscillator 44.55 3.25

Price Performance

Historical Comparison
LGVN
MDCX

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

About MDCX Medicus Pharma Ltd.

Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

Share on Social Networks: